Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 58Multiple Myeloma 52Leukemia 48Leukemia, Myeloid, Acute 44Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Myelodysplastic Syndromes 37Lymphoma, Non-Hodgkin 37Hodgkin Disease 36Lymphoma, Mantle-Cell 26Lymphoma, Large B-Cell, Diffuse 26Leukemia, Lymphocytic, Chronic, B-Cell 25Lymphoma, Follicular 22Breast Neoplasms 22Burkitt Lymphoma 21Lymphoma, B-Cell, Marginal Zone 16Congenital Abnormalities 15Lymphoma, Large-Cell, Immunoblastic 14Recurrence 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Sarcoma 12Neoplasms, Plasma Cell 12Hematologic Neoplasms 10Leukemia, Myelomonocytic, Juvenile 9Leukemia, Biphenotypic, Acute 9Blast Crisis 9Neoplasms 8Myeloproliferative Disorders 8Leukemia, Myelomonocytic, Chronic 8Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 7Neuroblastoma 7

Interventions

Valganciclovir 2Rituximab 2tocilizumab 1human papillomavirus vaccine, L1 type 16, 18 1Zidovudine 1Watchful Waiting 1Vincristine 1Tobacco Use Cessation Devices 1Surveys and Questionnaires 1Sugars 1Rapid Diagnostic Tests 1Prednisone 1Observation 1Methotrexate 1Maltose 1Light Coagulation 1Leucovorin 1Laser Therapy 1Interviews as Topic 1Interferon-alpha 1Imiquimod 1Fluorouracil 1Filgrastim 1Etoposide 1Enzyme-Linked Immunosorbent Assay 1Electrocoagulation 1Doxorubicin 1Cyclophosphamide 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Acquired Immunodeficiency Syndrome × Filgrastim × Clear all
NCT00006436 2025-12-30

EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
68 enrolled 24 charts
Lymphoid

Acquired Immunodeficiency Syndrome, Neoplasms, Lymphoma, Large B-Cell, Diffuse, Lymphoma, AIDS-Related

Data powered by HemOnc (CC BY 4.0) Colophon âš¡